Researchers called 87 IV drip clinics with cold symptoms. Most sold them something.

An intravenous line is a medical act. It bypasses every defence the body has between the outside world and the bloodstream. In hospital, placing one is documented, supervised and justified.

In a strip mall, it is increasingly a retail transaction — and a study appearing in the December issue of JAMA Internal Medicine is the first systematic attempt to describe what that transaction actually involves [s1].

What the researchers did

The study is mixed-methods and has three parts [s1][s3].

First, the authors reviewed the laws, policies and official statements of all 50 states and the District of Columbia, assessing each against four areas of oversight: governance, prescriber credentials, dispensing practices and compounding practices [s1][s3].

Second, they analysed 255 facility websites — five IV clinic sites per state [s1][s2].

Third, they ran a secret-shopper study, calling 87 facilities as prospective customers presenting with a headache and cold symptoms [s1][s3].

The assessment of state policy was as of June 2024 [s1][s3].

What they found

On regulation: 32 states had issued some policy or statement touching IV clinics, but only four — Alabama, North Carolina, South Carolina and Vermont — addressed all four oversight areas [s1]. As of June 2024, no state had enacted legislation specifically regulating IV hydration spas as a category [s2].

On what is being sold: every site in the sample offered IV hydration therapy. The most common additives were magnesium (57.3%) and glutathione (53.7%) [s1], with nicotinamide adenine dinucleotide at 51% [s2]. Nearly two-thirds of sites (63.5%) offered vitamin injections [s1]. Prescription pharmaceuticals appeared too: ketorolac at 25.5% of sites and ondansetron at 26.3% [s2]. More than a quarter (27.5%) offered GLP-1 weight-loss drugs [s2].

On evidence: virtually all sites made health benefit claims. Two of the 255 — 0.8% — cited a source for them [s1].

On the phone calls: 86.2% of facilities recommended a specific therapy for the caller's headache and cold symptoms [s1]. Only 27.6% required a consultation with a licensed medical professional [s1]. Just 24.4% described potential risks [s1].

The authors concluded that more stringent oversight of IV hydration spas may be necessary to protect public health [s1].

What this does and does not establish

This is a descriptive study. It measures what facilities advertise and what they say on the telephone. It does not measure harm, and it should not be read as an incidence estimate for complications from IV therapy. Nobody knows that number, which is part of the point — there is no adverse-event reporting system that would capture it.

The state-policy scan is a snapshot from June 2024, and the landscape has moved since. Texas enacted HB 3749, effective 1 September 2025, requiring that IV therapy be administered by a physician, physician assistant, advanced practice registered nurse or registered nurse [s2].

The secret-shopper design also has a known limitation: a facility's telephone script is not necessarily its clinical practice. A clinic that recommends a drip on the phone may still assess the customer on arrival.

The specific risk that regulation is aimed at

The four oversight areas the study used are not arbitrary. Each maps onto a documented failure mode.

Prescriber credentials matter because an infusion is a prescription act. The study's authors point to a 2024 death in Texas following an IV infusion administered by an unlicensed provider [s2].

Compounding matters because sterility failures in compounded infusions cause bloodstream infection. The FDA issued a warning in 2021 following a case of septic shock [s2].

Peter G. Lurie, president of the Center for Science in the Public Interest and a co-author, framed the gap bluntly: strip malls are filling with IV spas, and there is little evidence of health benefit alongside little regulation [s2]. Co-author Joseph S. Ross of Yale raised a second-order concern — that the clinics may divert patients from care they need, and IV fluids from hospitals that need them [s2].

The industry is estimated to take in hundreds of millions of dollars a year [s2].

What to watch

Whether other states follow Texas with credentialing statutes, and whether any state builds an adverse-event reporting requirement into them. Without the second, the harm question stays unanswerable, and every future study will be forced to describe marketing rather than outcomes.

This article is informational and is not medical advice.